Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIX001 for Cognitive Impairment in Post-Acute COVID-19 Syndrome
NCT05947617Phase 1Unknown
- Sponsor
- Neobiosis
- Start
- Oct 2023
- Primary completion
- Apr 2025
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 1, open-label trial of VIX001 in post acute COVID-19 syndrome (3 arms), sponsored by Neobiosis. Primary endpoints: Treatment-Emergent Adverse Events, Six Minute Walk Test with oximetry at Day 180 and 8 more. Status: unknown.
02
Drugs
VIX001
03
Conditions
post acute COVID-19 syndrome
Beyond the preview
Go deeper on NCT05947617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05947617.